TP53 and breast carcinoma: To characterize the clinicopathological relevance of TP53 mutations in breast cancer, we first divided all selected patients in each of the two cohorts from databases into wild‐type and mutant TP53 groups, and then analyzed the correlations between TP53 mutations and clinicopathological parameters.